$106 Million is the total value of DAFNA Capital Management LLC's 49 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 32.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMPE | Sell | AMPIO PHARMACEUTICALS INC | $11,700,000 | +13.3% | 1,401,146 | -13.8% | 11.09% | +25.0% |
| ATRC | ATRICURE INC | $10,495,000 | -2.3% | 570,987 | 0.0% | 9.95% | +7.7% | |
| PCYC | Buy | PHARMACYCLICS INC | $10,373,000 | -6.4% | 115,628 | +4.5% | 9.83% | +3.2% |
| DSCO | DISCOVERY LABORATORIES INC | $10,144,000 | -17.2% | 5,698,739 | 0.0% | 9.61% | -8.7% | |
| NXTM | NXSTAGE MEDICAL INC | $5,520,000 | +12.8% | 384,154 | 0.0% | 5.23% | +24.4% | |
| STXS | STEREOTAXIS INC | $4,904,000 | -16.5% | 1,381,460 | 0.0% | 4.65% | -7.9% | |
| DSCI | DERMA SCIENCES INC | $4,448,000 | -8.8% | 384,794 | 0.0% | 4.22% | +0.5% | |
| NVDQ | NOVADAQ TECHNOLOGIES INC | $4,343,000 | -26.0% | 263,541 | 0.0% | 4.12% | -18.4% | |
| PODD | INSULET CORP | $4,341,000 | -16.3% | 109,418 | 0.0% | 4.11% | -7.8% | |
| PLX | PROTALIX BIOTHERAPEUTICS INC | $4,301,000 | -20.3% | 1,178,440 | 0.0% | 4.08% | -12.1% | |
| New | INSULET CORPnote 2.000% 6/1 | $2,675,000 | – | 2,407,000 | +100.0% | 2.54% | – | |
| BOTA | BIOTA PHARMACEUTICALS INC | $2,080,000 | -53.4% | 729,781 | 0.0% | 1.97% | -48.6% | |
| GLMD | Buy | GALMED PHARMACEUTICALS LTD | $2,007,000 | -13.4% | 206,100 | +2.0% | 1.90% | -4.5% |
| BSTC | BIOSPECIFICS TECHNOLOGIES | $1,890,000 | +4.0% | 70,088 | 0.0% | 1.79% | +14.7% | |
| CRDC | Buy | CARDICA INC | $1,694,000 | +60.6% | 1,486,004 | +41.0% | 1.60% | +77.0% |
| BEAT | Buy | BIOTELEMETRY INC | $1,690,000 | -22.3% | 235,645 | +9.3% | 1.60% | -14.3% |
| THLD | Buy | THRESHOLD PHARMACEUTICAL INC | $1,556,000 | +20.8% | 393,000 | +45.3% | 1.48% | +33.2% |
| ADHD | Buy | ALCOBRA LTD | $1,471,000 | +740.6% | 84,996 | +783.4% | 1.39% | +829.3% |
| APPY | Buy | VENAXIS INC | $1,467,000 | +664.1% | 658,000 | +801.4% | 1.39% | +742.4% |
| KERX | Sell | KERYX BIOPHARMACEUTICALS | $1,421,000 | -16.6% | 92,400 | -7.6% | 1.35% | -8.1% |
| OCRX | Buy | OCERA THERAPEUTICS INC | $1,227,000 | +84.0% | 160,622 | +154.1% | 1.16% | +103.0% |
| UPI | Buy | UROPLASTY INC | $1,184,000 | +12.8% | 441,859 | +52.7% | 1.12% | +24.4% |
| XNPT | Buy | XENOPORT INC | $1,160,000 | +1.9% | 240,190 | +9.1% | 1.10% | +12.4% |
| NUVASIVE INCnote 2.750% 7/0 | $1,146,000 | -4.0% | 1,000,000 | 0.0% | 1.09% | +5.8% | ||
| ECIA | New | ENCISION INC | $1,126,000 | – | 1,062,500 | +100.0% | 1.07% | – |
| JNJ | JOHNSON AND JOHNSON | $983,000 | +6.5% | 9,400 | 0.0% | 0.93% | +17.5% | |
| SPNC | SPECTRANETICS CORP | $965,000 | -24.5% | 42,162 | 0.0% | 0.92% | -16.7% | |
| CYTR | CYTRX CORP | $941,000 | +19.9% | 225,000 | 0.0% | 0.89% | +32.1% | |
| ELOS | SYNERON MEDICAL LTD | $939,000 | -17.0% | 90,947 | 0.0% | 0.89% | -8.5% | |
| CUTR | CUTERA INC | $922,000 | -7.1% | 88,694 | 0.0% | 0.87% | +2.5% | |
| EXAC | EXACTECH INC | $798,000 | +11.9% | 31,636 | 0.0% | 0.76% | +23.3% | |
| RTIX | RTI SURGICAL INC | $727,000 | +6.6% | 167,058 | 0.0% | 0.69% | +17.6% | |
| FATE | New | FATE THERAPEUTICS INC | $479,000 | – | 75,930 | +100.0% | 0.45% | – |
| ICPT | INTERCEPT PHARMACEUTICALS IN | $473,000 | -28.3% | 2,000 | 0.0% | 0.45% | -21.0% | |
| LPTN | LPATH INC | $417,000 | -16.4% | 105,000 | 0.0% | 0.40% | -7.9% | |
| MASI | MASIMO CORPORATION | $413,000 | -13.6% | 17,500 | 0.0% | 0.39% | -4.9% | |
| SCYX | New | SCYNEXIS INC | $401,000 | – | 50,000 | +100.0% | 0.38% | – |
| ARDX | New | ARDELYX INC | $399,000 | – | 25,000 | +100.0% | 0.38% | – |
| TNXP | TONIX PHARMACEUTICALS HLDG C | $359,000 | +38.1% | 25,000 | 0.0% | 0.34% | +52.5% | |
| CRIS | CURIS INC | $279,000 | -34.0% | 150,000 | 0.0% | 0.26% | -27.5% | |
| CLTX | CELSUS THERAPEUTICS PLCsponsored adr ne | $272,000 | -4.6% | 43,900 | 0.0% | 0.26% | +5.3% | |
| BLFS | New | BIOLIFE SOLUTIONS INC | $265,000 | – | 116,279 | +100.0% | 0.25% | – |
| GNVC | GENVEC INC | $257,000 | -3.0% | 100,000 | 0.0% | 0.24% | +7.0% | |
| NSPR | Sell | INSPIREMD INC | $248,000 | -71.7% | 84,226 | -70.6% | 0.24% | -68.8% |
| RGDO | New | REGADO BIOSCIENCES INC | $204,000 | – | 30,000 | +100.0% | 0.19% | – |
| CEMI | CHEMBIO DIAGNOSTICS INC | $189,000 | -0.5% | 55,202 | 0.0% | 0.18% | +9.8% | |
| LMNS | New | LUMENIS LTD | $92,000 | – | 9,478 | +100.0% | 0.09% | – |
| NWBO | New | NORTHWEST BIOTHERAPEUTICS IN | $81,000 | – | 12,017 | +100.0% | 0.08% | – |
| RVP | RETRACTABLE TECHNOLOGIES INC | $50,000 | -34.2% | 20,000 | 0.0% | 0.05% | -27.7% | |
| AVEO | Exit | AVEO PHARMACEUTICALS INC | $0 | – | -261,507 | -100.0% | -0.34% | – |
| IMUC | Exit | IMMUNOCELLULAR THERAPEUTICS | $0 | – | -566,680 | -100.0% | -0.59% | – |
| ADMP | Exit | ADAMIS PHARMACEUTICALS CORP | $0 | – | -125,000 | -100.0% | -0.68% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -12,600 | -100.0% | -0.75% | – |
| MACK | Exit | MERRIMACK PHARMACEUTICALS IN | $0 | – | -514,853 | -100.0% | -2.23% | – |
| Exit | INSULET CORPnote 3.750% 6/1 | $0 | – | -2,625,000 | -100.0% | -4.08% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.